Development of a next-generation multipurpose robotic production facility
First written in FY2016. 7 of 11 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Building A of the Cybernics Medical Innovation Base is operating in the Tonomachi International Strategic Zone in Kawasaki, promoting the systematization of cybernics therapies combining HAL with regenerative medicine and pharmaceuticals, as well as the development of technologies integrating medical and biotechnology with AI, robotics, and information technology. The company is advancing the move-in of life sciences companies, with business synergies anticipated, and collaboration with C-Startup partners in regenerative medicine and drug discovery.」
The company has reconfirmed its policy of operating a research and business base through the operation of Building A at Tonomachi, the move-in of life sciences companies, and collaboration with partners in regenerative medicine and drug discovery. - FY2025-H1RestatedAnnual report
「Building A of the Cybernics Medical Innovation Base is operating in the Tonomachi International Strategic Zone in Kawasaki, also known as King Skyfront. The facility promotes the systematization of cybernics therapies combining HAL® with regenerative medicine and pharmaceuticals, as well as the development of technologies integrating medical and biotechnology with AI, robotics, and information technology. The company is advancing the move-in of life sciences companies, with business synergies anticipated, and collaboration with C-Startup partners in regenerative medicine and drug discovery.」
The company has reconfirmed its policy of operating Building A at Tonomachi, advancing combination therapies involving HAL, regenerative medicine, and pharmaceuticals, integrating medical and biotechnology with AI, robotics, and information technology, and pursuing business synergies with partner companies. - FY2024-Q3RestatedAnnual report
「At the Tonomachi International Strategic Zone in Kawasaki, also known as King Skyfront, Building A of the Cybernics Medical Innovation Base, which promotes the development of new medical technologies combining cybernics therapies such as HAL® with regenerative medicine and drug discovery, was completed. Since January 2023, life sciences companies, including C-Startup partners in regenerative medicine and drug discovery, have been moving into the facility. The company will continue to select collaboration partners in stages, with business synergies anticipated.」
The company has reconfirmed the completion of Building A at Tonomachi, the move-in of life sciences companies since January 2023, and its policy of selecting collaboration partners going forward. - FY2020AdvancedAnnual report
「April 2020: The next-generation multipurpose robotic production facility, Fukushima Site, registered as a medical device manufacturing business」
Regarding the next-generation multipurpose robotic production facility, the Fukushima Site obtained registration as a medical device manufacturing business, bringing preparations for medical device manufacturing to the formal registration stage. - FY2019AdvancedAnnual report
「We continue to make capital expenditures aimed at strengthening administrative functions and enhancing research and development capabilities. Capital expenditures for the current consolidated fiscal year totaled ¥789 million, mainly consisting of partial payments toward the acquisition of land in Tsukuba, Ibaraki Prefecture.」
Capital expenditures to strengthen administrative and research and development functions continued, with ¥789 million invested during the year. The acquisition of land in Tsukuba is also being advanced. - FY2018AdvancedAnnual report
「Total capital expenditures for the current consolidated fiscal year were ¥1,126 million, mainly consisting of spending at the Tonomachi International Strategic Zone in Kawasaki, Kanagawa Prefecture, and partial payments toward the acquisition of land in Tsukuba, Ibaraki Prefecture.」
Capital expenditures related to the Tonomachi facility in Kawasaki and the acquisition of land in Tsukuba are being advanced, with total capital expenditures of ¥1,126 million recorded. No separate plan for the construction of significant facilities is disclosed. - FY2017AdvancedAnnual report
「Total capital expenditures for the current consolidated fiscal year were ¥6,610.490 million, mainly consisting of partial payments toward the acquisition of land and other assets in Gakuen-no-Mori, Tsukuba, Ibaraki Prefecture.」
Capital expenditures of ¥6,610.490 million were recorded, and the acquisition of land in Gakuen-no-Mori, Tsukuba, was advanced. The land investment was planned for completion in March 2019. - FY2017-Q3AdvancedAnnual report
「Total assets at the end of the third quarter of the current consolidated fiscal year decreased by ¥569.998 million from the end of the previous consolidated fiscal year to ¥46,964.471 million. This was mainly due to decreases of ¥3,754.948 million in cash and deposits and ¥2,500.386 million in securities, partly offset by an increase of ¥4,969.341 million in construction in progress.」
Construction in progress related to development of the next-generation multipurpose robotic production facility increased by ¥4,969.341 million from the end of the previous consolidated fiscal year, reflecting progress in construction investment in the financial figures. - FY2017-Q2AdvancedAnnual report
「This was mainly due to decreases of ¥4,209.569 million in cash and deposits and ¥1,499.848 million in securities, and increases of ¥4,964.107 million in construction in progress and ¥307.764 million in buildings and structures, net.」
Construction in progress, apparently related to the next-generation multipurpose robotic production facility, increased by ¥4,964.107 million from the end of the previous consolidated fiscal year, while buildings and structures also increased by ¥307.764 million. This is treated as progress in construction investment rather than completion. - FY2017-Q1AdvancedAnnual report
「This was mainly due to an increase of ¥5,623.635 million in construction in progress and decreases of ¥4,091.326 million in cash and deposits and ¥1,499.980 million in securities.」
The increase in construction in progress is reflected in the financial position. It is treated as a financial change indicating progress in construction investment rather than as completion of the plant. - FY2016First statedAnnual report
「This represents an investment of ¥648.251 million for the construction of a next-generation multipurpose robotic production facility (provisional name).」
A facility is being developed in Koriyama, Fukushima Prefecture, to handle the development, production, and training of HAL and medical-care systems. The planned total investment is ¥1.1 billion, with completion scheduled for July 2016.